Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „Disperzi“
Suchtreffer
Begriffe & Kennungen
Olazax Disperzi · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax Disperzi · 4.8 · 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Follow
Eintrag öffnenOlazax Disperzi · 4.8 · 10 12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper
Eintrag öffnenOlazax Disperzi · 4.8 · 10 As assessed by measured values from clinical trials in the Olanzapine Integrated Database. 11 Adverse event
Eintrag öffnenOlazax Disperzi · 4.8 · 11 Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4.4). Investigations Very common
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax Disperzi · 4.8 · 24 Dysarthria
Eintrag öffnenOlazax Disperzi · 4.8 · 25 section 4.6) Reproductive system and breast disorders Erectile dysfunction in Amenorrhea Priapism12 males B
Eintrag öffnenOlazax Disperzi · 4.8 · 26 8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal
Eintrag öffnenOlazax Disperzi · 4.8 · 27 Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The fre
Eintrag öffnenOlazax Disperzi · 4.8 · 40 syndrome11 Cardiac disorders Bradycardia Ventricular QTc prolongation tachycardia/fibri (see section 4.4) l
Eintrag öffnenOlazax Disperzi · 4.8 · 41 males and females females Gynaecomastia/bre ast enlargement in males General disorders and administration s
Eintrag öffnenOlazax Disperzi · 4.8 · 42 10 As assessed by measured values from clinical trials in the Olanzapine Integrated Database. 11 Adverse ev
Eintrag öffnenOlazax Disperzi · 4.8 · 43 Metabolism and nutrition disorders Very common: Weight gain 13, elevated triglyceride levels 14, increased
Eintrag öffnenOlazax Disperzi · 4.8 · 55 akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, an
Eintrag öffnenOlazax Disperzi · 4.8 · 56 embolism and deep vein thrombosis) (see section 4.4) Respiratory, thoracic and mediastinal disorders Epista
Eintrag öffnenOlazax Disperzi · 4.8 · 57 Investigations Elevated plasma Increased alkaline Increased total prolactin levels8 phosphatase10 bilirubin
Eintrag öffnen